Probiotics Clinical Trial
— PROfficial title:
The Effect of Gastric Acid Suppression on Probiotic Colonization
Verified date | February 2020 |
Source | Stanford University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Probiotics are over-the-counter dietary products with microorganisms that are generally consumed for health benefit. However, the durability of these microorganisms is unclear, particularly when they pass through the highly acidic environment of the stomach. We will test the colonization of these microorganisms among individuals who consume probiotics with and without acid suppression therapy.
Status | Completed |
Enrollment | 39 |
Est. completion date | December 30, 2018 |
Est. primary completion date | December 30, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Healthy volunteers ages 18 years and = 75 years. - Able to visit the study Doctor's office 3 times, answer 3 questionnaires, and provide stools and blood samples. Exclusion Criteria: - Gastric cancer, Barrett's esophagus cancer, any gastrointestinal condition, or soy or gluten sensitivity - Previous abdominal surgery - Currently pregnant or nursing - Had H. Pylori Infection - Diagnosed with any chronic medical condition other than hypertension or hyperlipidemia - Currently consuming herbs or probiotics |
Country | Name | City | State |
---|---|---|---|
United States | Stanford University | Palo Alto | California |
Lead Sponsor | Collaborator |
---|---|
Stanford University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Relative Abundance of VSL#3 Probiotic Bacterial Strains When Ingested in the Presence or Absence of the Proton Pump Inhibitor (PPI) Omeprazole at Week 4. | Relative abundance is reported as the percent of combined VSL #3 probiotic bacteria strains in the bacteria sample (S. thermophiles, B. breve, B. longum, B. infantis, L. acidophilus, L. plantarum, L. paracasei, L. delbrueckii subsp. bulgaricus) following their ingestion in the presence or absence of the gastric acid suppression drug omeprazole. Stool samples were assessed. | Week 4 | |
Secondary | Number of Participants With Symptoms Related to VSL#3 Treatment. | Participants were asked to report symptoms of gastro-intestinal discomfort experienced within the last 28 days. | Week 0 through Week 4 | |
Secondary | Relative Abundance (Mean Value) of Most Abundant Bacterial Phylum Before and After VSL#3 Probiotic Administration | From week 0 to week 4, change in the relative abundance (percentage) of most common types of bacteria phyla normally found in the lower GI track (e.g. Firmicutes, Bacteroidetes, Actinobacteria and Proteobacteria) after ingesting VSL#3 in the presence or absence of omeprazole. Stool samples are assessed. | Week 0 and Week 4 | |
Secondary | Change in Peak Intensity of the Metabolite 1H-Indole-4-carbaldehyde Before and After VSL#3 Probiotic Administration (Omeprazole and VSL #3). | From week 0 to week 4, relative change in metabolites (e.g. short chain fatty acids, bile acid derivatives, flavonoids, amino acids) found in the GI track by mass spectrometry after ingesting VSL#3. Serum samples are assessed. MZ = mass/charge ratio; RT = retention time. MZ/RT data were obtained by mass spectrometry analysis. This is a metabolite of interest for the Omeprazole and VSL#3 group only. |
Week 0 and Week 4 | |
Secondary | Change in Peak Intensity of Metabolites of Interest Before and After VSL#3 Probiotic Administration (Placebo and VSL#3 Group). | From week 0 to week 4, relative change in metabolites (e.g. short chain fatty acids, bile acid derivatives, flavonoids, amino acids) found in the GI track by mass spectrometry after ingesting VSL#3. Serum samples are assessed. MZ = mass/charge ratio; RT = retention time. MZ/RT data were obtained by mass spectrometry analysis. These are metabolites of interest for the Placebo and VSL#3 group only. |
Week 0 and Week 4 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
Recruiting |
NCT06323642 -
Role of Probiotics as Adjunct Therapy Along With Standard Care in Decreasing Hospital Stay and Improving Symptoms in Pediatric Patients Admitted With Severe Pneumonia
|
N/A | |
Completed |
NCT03556631 -
Effect of Live Combined Bifidobacterium and Lactobacillus on Glycemic Control and Other Outcomes in Type 1 Diabetes
|
Phase 4 | |
Completed |
NCT04043000 -
Super 13 Pro & Prebiotics on the Human Intestinal Microflora
|
N/A | |
Completed |
NCT04289337 -
Double-blind Clinical Trials of Probiotic Products in Oral Health.
|
N/A | |
Not yet recruiting |
NCT03967301 -
Prevention and Decolonization of Multidrug-resistant Bacteria With Probiotics
|
N/A | |
Completed |
NCT02207140 -
Effect of Multi-species Probiotic HOWARU® Restore, on Gut Microbiota of Elderly
|
Phase 0 | |
Completed |
NCT01201577 -
Biological Modulation of Bacterial QSSMs, Innate and Adaptive Immunity by Antibiotics, Probiotics and Prebiotics in Healthy Individuals
|
Phase 1 | |
Not yet recruiting |
NCT06063226 -
Clinical and Microbiological Aspects of Probiotics in Non-surgical Periodontal Therapy.
|
N/A | |
Recruiting |
NCT05588674 -
The Effect of Probiotics on Exercise Performance and Recovery
|
N/A | |
Completed |
NCT05798689 -
Use of a Selected Mixture of Probiotic Strains for Degrading Gluten During Digestion
|
N/A | |
Completed |
NCT03167593 -
Effects of Lactobacillus Coryniformis CECT5711 on Immune Response to Influenza Vaccination in Adults Over 65.
|
Phase 2 | |
Completed |
NCT05073393 -
Effect of Probiotics on Oral Homeostasis During Sugar Stress
|
N/A | |
Completed |
NCT02971787 -
Salt Intake and Lactobacillus Abundance
|
N/A | |
Recruiting |
NCT02005003 -
Cognitive and Metabolic Effects of a Probiotic Supplement
|
N/A | |
Recruiting |
NCT05657730 -
Study the Effect of Water Kefir Consumption on the Gut Microbiome in Healthy Adults
|
N/A | |
Completed |
NCT03499184 -
Adjunctive Probiotics in Chronic Periodontitis
|
N/A | |
Enrolling by invitation |
NCT04527055 -
The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication
|
Phase 4 | |
Recruiting |
NCT05337670 -
Probiotics Regulates Skin Care in Children
|
N/A | |
Recruiting |
NCT05005611 -
Probiotics Regulates Skin Care in Children
|
N/A |